HOUSE 5850118th CongressReferred to the Subcommittee on Health.

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Last Action: 10/6/2023

Actions

2023-10-06Referred to the Subcommittee on Health.
2023-09-29Referred to the House Committee on Energy and Commerce.
2023-09-29Introduced in House
2023-09-29Introduced in House

Cosponsors (1)

John Moolenaar (R-MI)

Subjects

Abortion
Drug safety, medical device, and laboratory regulation
Prescription drugs

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.